Skip to content
lifestyle.goodsciencing.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
OnKure Therapeutics, Inc.
OnKure Therapeutics to Host Virtual KOL Event to Discuss PI3Kα Inhibitor Medicines: Selectivity Matters & Pan-Mutant Allosteric Inhibition Delivers, on July 15, 2026
July 2, 2026
OnKure Therapeutics Reports First Quarter 2026 Financial Results
May 5, 2026
OnKure Therapeutics Announces Oversubscribed $150 Million Private Placement to Advance Next-Generation PI3Kα Pan-Mutant Selective Inhibitor Candidates in Breast Cancer and Vascular Anomalies
March 27, 2026
OnKure Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results
March 12, 2026